New Launch3 Apr 2025, 05:49 pm
Shilpa Medicare's Marketing Partner Amneal Pharmaceuticals Launches Ready-to-Use Bortezomib Injection in US
AI Summary
Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new product reduces the compounding preparation steps typically required with administration and has been granted a permanent J-code by the U.S. Centers for Medicare & Medicaid Services (CMS). BORUZU, a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma, and it references the branded product Velcade®.
Key Highlights
- Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, launches BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration
- New product reduces the compounding preparation steps typically required with administration
- Product has been granted a permanent J-code by the U.S. Centers for Medicare & Medicaid Services (CMS)
- BORUZU is used for the treatment of multiple myeloma and mantle cell lymphoma
- New launch demonstrates Shilpa Medicare’s capabilities and commitment to introduce pharmacy efficient solutions